Stock Price Targets: What They Mean and the Latest News
A price target is where an analyst thinks a stock will trade in about a year. Analysts at banks and research firms publish them with a rating such as buy, hold or sell.
Stories about price targets usually report a change. A raised target means the analyst has grown more hopeful. A cut means the opposite. One target matters less than the trend. When many analysts raise their targets at once, it often follows strong results or a better outlook.
Follow price targets news without checking every day
One email every Monday with the week's biggest moves and the stories behind them. Free, unsubscribe anytime.
50 articles
Market Mood
Latest price targets news
H.C. Wainwright Maintains Gevo (GEVO) Stock Price Target at $14
H.C. Wainwright has maintained its stock price target for Gevo (GEVO) at $14. This decision reflects the firm's continued outlook on the company's valuation and potential. The stock target indicates the analyst's expectation for future stock performance, providing a benchmark for investors and company stakeholders. Currently, there is no change in the expectation from the previous target, suggesting that the firm's outlook on Gevo remains stable. Generally, maintaining a price target can influence investor expectations and market behavior towards the stock. The reaffirmation of the target price suggests confidence in Gevo's potential and may act as a guide for investors seeking direction on their investment. Price targets can inform market sentiment, though they are not guarantees of future performance. This matters to ordinary investors because the maintained target provides a clear benchmark for what analysts expect the stock to reach, offering a gauge for investment decisions.
Read More: H.C. Wainwright Maintains Gevo (GEVO) Stock Price Target at $14
Cantor Fitzgerald Cuts Arthur J. Gallagher Price Target
Cantor Fitzgerald has lowered its price target for Arthur J. Gallagher (AJG) following reductions in the company's earnings per share (EPS) estimates. This move suggests a cautious outlook on Arthur J. Gallagher's financial performance, as analysts at Cantor Fitzgerald have adjusted their expectations based on revised EPS forecasts. The exact figures related to the price target adjustment were not disclosed in the article. The decision to lower the price target comes amid adjustments to earnings expectations, which may affect investor perceptions of the company's valuation. Price targets are important for investors as they provide an estimate of a stock's future value, based on revised analyses by financial experts. For regular investors, such changes in analyst ratings or opinions can signal potential shifts in a stock's potential upside or risk, influencing investment decisions.
Read More: Cantor Fitzgerald Cuts Arthur J. Gallagher Price Target
Foghorn Therapeutics (FHTX) Price Target Cut to $5 After Program Halt
H.C. Wainwright has reduced the price target for Foghorn Therapeutics (FHTX) to $5 following a halt in one of its programs. This adjustment reflects concerns over the company's prospects in the market after the program's interruption. The move signals a shift in analyst sentiment, potentially influencing investor confidence and stock performance. For ordinary investors, this means adjusted expectations for Foghorn's stock value, which could impact investment decisions.
Read More: Foghorn Therapeutics (FHTX) Price Target Cut to $5 After Program Halt
BofA Downgrades Amrize (AMZ) on Growth Concerns, Cuts Price Target
Bank of America (BofA) has downgraded Amrize (AMZ) due to concerns about its growth prospects. The price target for the stock has been cut, although specific figures for the downgrade and revised target were not disclosed. This action indicates BofA's cautious outlook for Amrize amid potential challenges in its growth strategy. A downgrade from a major financial institution can negatively impact investor sentiment and stock performance, making it essential for investors to consider the implications of such ratings.
Read More: BofA Downgrades Amrize (AMZ) on Growth Concerns, Cuts Price Target
HSBC Raises Chevron (CVX) Price Target to $250
HSBC has increased its price target for Chevron (CVX) stock to $250, citing the company's sensitivity to oil price fluctuations. This is relevant as oil prices directly affect Chevron's revenue, with potential for substantial financial impact. The change in price target reflects analyst confidence in Chevron's performance in a volatile market. For investors, this adjustment may signify an opportunity as Chevron's stock could react positively to rising oil prices.
Read More: HSBC Raises Chevron (CVX) Price Target to $250
BioMarin Targets $100 with Bullish Call Spread by April 2027
BioMarin has seen significant bullish options activity with a large call spread targeting a price of $100 by April 2027. This options flow suggests investor confidence in BioMarin's future performance and potential price appreciation. Such bullish positions may indicate expectations for upcoming positive developments or financial results related to the company. For ordinary investors, this emphasizes a potential upward movement in BioMarin's share prices (BMRN) as market participants position themselves for future gains.
Read More: BioMarin Targets $100 with Bullish Call Spread by April 2027
Ovid Therapeutics (OVID) Price Target Raised to $5 Due to Pipeline Progress
H.C. Wainwright has increased its price target for Ovid Therapeutics (OVID) to $5, citing advancements in the company's pipeline. This increase reflects investor confidence in Ovid's ongoing development efforts. The raised target may influence market perceptions and trading behavior related to Ovid Therapeutics. A higher price target can suggest potential for better future performance of the stock, which is significant for investors monitoring biotech firms.
Read More: Ovid Therapeutics (OVID) Price Target Raised to $5 Due to Pipeline Progress
Morgan Stanley Raises Robinhood Price Target 21% to $150
Morgan Stanley increased its price target for Robinhood (HOOD) from $124 to $150, indicating a 21% rise. This upward revision reflects analysts’ confidence in Robinhood's growth potential, independent of cryptocurrency trading volatility. The adjustment highlights the firm's positive outlook on the online trading platform's future. For investors, this signifies potential upward momentum in Robinhood's stock price, as analysts remain optimistic about its performance.
Read More: Morgan Stanley Raises Robinhood Price Target 21% to $150
Nvidia (NVDA) Revenue Grows 85% with Price Target of $270.26
Nvidia (NVDA) reported an 85% revenue growth year-over-year, achieving $82 billion in its Q1 FY27 earnings. The company has a forward PEG (price/earnings-to-growth) ratio of 0.605 and is currently trading at $215.17, with a price target set at $270.26, suggesting a potential upside of 25.27% over the next 12 months. The guidance for Q2 FY27 is approximately $91 billion, excluding China data center compute. This matters for investors as strong revenue growth and high gross margins indicate solid profitability, bolstering market confidence in Nvidia's future prospects.
Read More: Nvidia (NVDA) Revenue Grows 85% with Price Target of $270.26
Bill.com (BILL) Price Target Raised to $60 by UBS
UBS has raised its price target for Bill.com (BILL) to $60, citing margin expansion as a key factor. The increase reflects confidence in the company's ability to improve profitability. Bill.com's recent performance suggests it is on a positive trajectory, which may enhance investor interest. This adjustment could influence trading volume and investor behavior as the stock approaches this new target price.
Read More: Bill.com (BILL) Price Target Raised to $60 by UBS
Eos Energy (EOS) Stock Price Target Cut Due to Revenue Outlook
B. Riley has reduced its price target for Eos Energy (EOS) following a tighter revenue outlook. The firm's adjustment suggests a cautious approach amid changing financial expectations for Eos Energy. This revision is significant as it may influence investor sentiment and trading activity around Eos Energy shares. Consequently, a lower target can indicate potential challenges ahead for company performance, affecting investors' decisions regarding their holdings.
Read More: Eos Energy (EOS) Stock Price Target Cut Due to Revenue Outlook
Glaukos (GKOS) Price Target Raised to $175 on iDose Outlook
Stifel has increased the price target for Glaukos (GKOS) to $175, reflecting a positive outlook for its iDose product. The adjustment suggests confidence in the product's market potential and could enhance investor sentiment. This revised target highlights Stifel's belief in growth prospects for Glaukos amid current market conditions. Such an increase may impact trading volumes and investor interest in Glaukos stock.
Read More: Glaukos (GKOS) Price Target Raised to $175 on iDose Outlook
Deutsche Bank Raises ASML (ASML) Price Target on Margin Outlook
Deutsche Bank has increased the price target for ASML (ASML), reflecting a revised outlook on its margins. The new target indicates a confidence in ASML's ability to improve its profitability. This adjustment in expectations may influence investor sentiment and trading behavior significantly. Understanding these changes is essential for investors looking to make informed decisions regarding ASML’s stock performance.
Read More: Deutsche Bank Raises ASML (ASML) Price Target on Margin Outlook
J&J Reports Strong Quarter, Price Target Raised Despite Stock Decline
Johnson & Johnson (JNJ) reported better-than-expected earnings and increased its guidance for the year. However, the stock fell despite this positive news. Analysts have raised their price targets based on the strong performance, indicating confidence in the company's future despite market reactions. The fluctuations highlight the complexities investors navigate in evaluating company performance against stock market responses.
Read More: J&J Reports Strong Quarter, Price Target Raised Despite Stock Decline
Ionis (IONS) Stock Price Target Cut to $95 After Trial Results
Canaccord has reduced its price target for Ionis Pharmaceuticals (IONS) to $95 following the company's trial misses. The revision reflects concerns regarding Ionis's pipeline and potential future earnings performance. This adjustment may influence investor perception and stock performance, especially as the markets react to updated forecasts. Such price target changes can indicate underlying issues that affect stock valuation and investor sentiment.
Read More: Ionis (IONS) Stock Price Target Cut to $95 After Trial Results
Hayward (HW) Buy Rating Reiterated with $19.50 Price Target
Stifel has reiterated a 'Buy' rating on Hayward Holdings (HW) with a price target of $19.50. This reaffirmation suggests analyst confidence in the company's growth potential. Target price indicates an upside based on current trading levels, which could influence investor sentiment and trading behavior. Analysts' ratings can impact market perceptions significantly, especially in the context of ongoing economic conditions.
Read More: Hayward (HW) Buy Rating Reiterated with $19.50 Price Target
Forbright (FBRG) Stock Initiated by JPMorgan with $21 Target
JPMorgan has initiated coverage on Forbright (FBRG) with a neutral rating. The firm has set a price target of $21 for the stock. This rating suggests that JPMorgan does not foresee significant upward movement in the stock price in the near term. The establishment of this target may influence trading volumes and investor decisions regarding FBRG shares as market participants assess the firm's outlook.
Read More: Forbright (FBRG) Stock Initiated by JPMorgan with $21 Target
Canopy Growth (CGC) Analyst Target at $1.22 Indicates 27% Upside
Canopy Growth (CGC) recently dropped below $1 per share despite a previous surge during the spring marijuana rally. The average analyst price target is currently $1.22, representing a potential 27% increase from its current trading price. Roth Capital Partners analyst Bill Kirk has set a more optimistic price target of 5 Canadian dollars, indicating a possible fourfold increase. However, Kirk's estimates for FY2027 project a modest 5.1% revenue growth, and adjusted EBITDA is expected to remain near breakeven, suggesting that significant gains may be challenging without favorable regulatory changes.
Read More: Canopy Growth (CGC) Analyst Target at $1.22 Indicates 27% Upside
Tesla (TSLA) stock price target raised to $420 after deliveries
Freedom Broker has increased the price target for Tesla (TSLA) to $420, citing recent delivery numbers as a key factor. The target adjustment reflects confidence in Tesla's operational performance and potential growth in market share. Price targets are essential metrics for investors as they provide insights into future stock performance. This news could influence trading sentiment around TSLA, particularly among analysts and investors watching performance metrics closely.
Read More: Tesla (TSLA) stock price target raised to $420 after deliveries
Deutsche Bank (DB) Stock Jumps 6% Following Price Target Increase
Deutsche Bank (DB) shares increased by 6% following comments from Morgan Stanley regarding the bank's price target. Specific details regarding the new price target were not disclosed in the article. This increase is significant as it reflects investor optimism based on analyst support, which can impact market sentiment towards the stock. The move could encourage further investment in Deutsche Bank shares, contributing to overall market dynamics in the banking sector.
Read More: Deutsche Bank (DB) Stock Jumps 6% Following Price Target Increase
IBM Price Target Raised to $267 by Morgan Stanley Amid Strong Demand
Morgan Stanley raised its price target on International Business Machines (IBM) from $225 to $267 on June 23, maintaining an 'Equal Weight' rating. The analyst noted that demand for enterprise servers is proving to be more inelastic than previously expected, despite price increases. EPS estimates for compute-exposed companies have been increased by 5% to 6%. Additionally, JPMorgan upgraded IBM to 'Overweight' with a price target of $291, showing increased confidence in the company's software business in the second half of 2026.
Read More: IBM Price Target Raised to $267 by Morgan Stanley Amid Strong Demand
Alibaba (BABA) Price Target Cut to $175 by Daiwa, Down from $200
Daiwa has reduced its price target for Alibaba Group Holding Limited (BABA) from $200 to $175 while maintaining a 'Buy' rating. This decision follows disappointing trends observed during China's 2026 618 shopping festival, indicating weakness in e-commerce consumption. The firm also noted challenges within the broader sector, including regulatory tightening and an unfavorable macroeconomic environment. Additionally, BABA is currently engaged in legal action against the Department of Defense regarding its designation on a blacklist.
Read More: Alibaba (BABA) Price Target Cut to $175 by Daiwa, Down from $200
Goldman Sachs Initiates Intel (INTC) Coverage with $150 Target
Goldman Sachs analyst James Schneider initiated coverage of Intel (INTC) with a Neutral rating and a price target of $150, suggesting a 12% upside. The firm expects Intel to benefit from rising server demand related to agentic AI, while also noting balanced risk/reward. In contrast, BofA raised its Intel price target to $160 from $135, supported by a forecast increase in the semiconductor industry's addressable market to $2.7 trillion by 2030. Mizuho also updated its Intel target to $135, highlighting long-term market share potential.
Read More: Goldman Sachs Initiates Intel (INTC) Coverage with $150 Target
Ionis (IONS) Stock Price Target Raised to $130 Following FDA Approval
H.C. Wainwright has increased Ionis Pharmaceuticals' (IONS) stock price target to $130 following FDA approval of a new treatment. This upgrade reflects a positive outlook for the company's future revenues and the anticipated impact on market share. An FDA approval typically drives higher investor confidence and market interest, potentially enhancing trading volumes and stock performance. The raise in target price indicates a belief in significant growth potential from this regulatory win.
Read More: Ionis (IONS) Stock Price Target Raised to $130 Following FDA Approval
Connect Biopharma Stock Rated Buy at $7 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating on Connect Biopharma (CNTB) stock, setting a price target of $7. This recommendation indicates confidence in the company's future performance and may influence investor sentiment. The current trading price suggests potential upside for investors based on the analyst's target. An affirmation from notable analysts can impact liquidity and trading volume as stakeholders evaluate their strategies.
Read More: Connect Biopharma Stock Rated Buy at $7 by H.C. Wainwright
MongoDB (MDB) Sees Billionaire Holdings Drop By $2.23B in 2026
MongoDB, Inc. (MDB) experienced a decline in billionaire holdings from $4.23 billion in Q4 2025 to $1.99 billion in Q1 2026, a decrease of about $2.23 billion. Despite this, analysts have raised price targets, with BofA raising its target to $450 from $390 and Tigress Financial increasing it to $515 from $430, both maintaining 'Buy' ratings. Scotiabank updated its target to $395 from $310, while Wedbush raised it to $390 from $380. MongoDB's fiscal 2027 results showed strong performance and a significant revenue guidance raise, particularly in Atlas consumption.
Read More: MongoDB (MDB) Sees Billionaire Holdings Drop By $2.23B in 2026
Rapid7 (RPD) Billionaire Stake Drops to $83.70 Million
Rapid7, Inc. (NASDAQ:RPD) saw a decline in billionaire investments, dropping from approximately $195.91 million in Q4 2025 to $83.70 million in Q1 2026, a fall of about $112.22 million. On June 1, 2026, analyst Rudy Kessinger from DA Davidson raised the price target from $5.25 to $6.50 while maintaining an 'Underperform' rating amidst leadership changes. CEO Corey Thomas transitioned to Executive Chairman, with Wael Mohamed appointed as new CEO. Barclays also adjusted its price target to $6.50 from $8, citing disappointing Q2 annual recurring revenue guidance as a rationale for reducing estimates.
Read More: Rapid7 (RPD) Billionaire Stake Drops to $83.70 Million
Netflix (NFLX) Targeted at $287 with 90% Confidence Rating
Netflix (NFLX) is currently trading at $76.96, with a 12-month price target of $287.04, indicating a potential upside of 272.98%. The company's ad revenue is projected to double to $3 billion by 2026, with a yearly increase in advertiser count of 70%. Despite a year-to-date share decline of 17.92% and a 36.95% drop over the past 12 months, 37 analyst Buy ratings support a bullish outlook. Management has raised their 2026 free cash flow guidance to $12.5 billion, reaffirming an operating margin target of 31.5%.
Read More: Netflix (NFLX) Targeted at $287 with 90% Confidence Rating
PebbleBrook Hotel Trust (PEB) Price Target Raised by Stifel
Stifel has increased its price target for PebbleBrook Hotel Trust (PEB) due to the strength of its portfolio. This adjustment reflects a positive evaluation of PEB's asset management and positioning within the market. The updated target could influence investor confidence and stock performance, enhancing the company's visibility among stakeholders. Such changes in analyst ratings are often critical indicators for market movements.
Read More: PebbleBrook Hotel Trust (PEB) Price Target Raised by Stifel
Oncology Institute (TOCI) Price Target Raised to $7 by Needham
Needham has raised its price target for Oncology Institute (TOCI) to $7, reflecting a positive growth outlook. This adjustment indicates confidence in the company's future performance and may influence investor sentiment. The raised target suggests a potential upside, which could affect market activity around TOCI shares. Analysts are highlighting the company's growth prospects as a key factor behind the revised target.
Read More: Oncology Institute (TOCI) Price Target Raised to $7 by Needham
Enbridge (ENB) Trading Near 52-Week High With 26% Upside Target
Enbridge (ENB) is currently trading at $55.94, 11% below its 52-week high of $58.45. Analysts from 24/7 Wall St. have set a price target of $70.51, suggesting a potential upside of 26.04%. Year-to-date, shares have increased by 20.09%, with a 26.61% rise over the past year. Enbridge boasts a $40 billion secured backlog and 31 consecutive years of dividend hikes, yielding 6.9% for investors, although it faces risks including a debt-to-EBITDA ratio of 5.0x.
Read More: Enbridge (ENB) Trading Near 52-Week High With 26% Upside Target
Zhipu (Ticker: ZHIP) Shares Surge 48% After Price Target Increase
Zhipu shares experienced a 48% increase following JPMorgan's raise of their price target. This substantial rise in stock price indicates a positive sentiment in the market regarding Zhipu's future potential. The adjustment by JPMorgan may suggest higher growth prospects for the company, influencing investor confidence and trading activity in ZHIP shares. Such developments can impact Zhipu's overall market performance and valuation.
Read More: Zhipu (Ticker: ZHIP) Shares Surge 48% After Price Target Increase
Broadcom (AVGO) Reports $22.19B Revenue, Down 12.9% Monthly
Broadcom Inc. (AVGO) reported $22.19 billion in revenue for Q2 2026, missing analyst estimates of $22.27 billion. The company's shares have decreased by 12.9% over the past month, largely following this earnings report. Firms such as Benchmark and DA Davidson have adjusted their price targets, setting new targets at $545 and $400 respectively. Despite the volatility and missed guidance, analysts have maintained a Buy and Neutral rating on Broadcom, with ongoing discussions surrounding its position in the semiconductor market.
Read More: Broadcom (AVGO) Reports $22.19B Revenue, Down 12.9% Monthly
HPE Quarterly Revenue Up 40% to $10.7B, Price Target Raised to $70
Hewlett Packard Enterprise Company (HPE) reported quarterly revenue of $10.7 billion, representing a 40% increase year over year. Earnings per share rose to $0.79, an increase of $0.41. Argus raised its price target for HPE from $30 to $70 based on the company's strong performance and positive outlook on AI integration. The firm noted a significant increase in cash flow from operations, which grew to $1.4 billion, supported by a free cash flow increase to $0.9 billion. These results underscore HPE’s growing position in enterprise technology and networking solutions.
Read More: HPE Quarterly Revenue Up 40% to $10.7B, Price Target Raised to $70
Modine Manufacturing (MOD) Price Target Raised to $428 Amid Growth
GLJ Research reiterated a Buy rating on Modine Manufacturing (MOD) on June 1, raising its price target to $428. The company increased its 2028 revenue guidance beyond current capacity and announced a long-term capacity agreement with a hyperscaler customer. Revenue for Q4 FY2026 rose 47% to $954.4 million, while net earnings also increased 47% to $73.3 million. The full-year net sales grew 23% to $3.2 billion, though net earnings for the year decreased by 34% to $123.3 million, indicating strong growth in sales but challenges in profitability.
Read More: Modine Manufacturing (MOD) Price Target Raised to $428 Amid Growth
Street Calls of the Week Highlight Key Stock Movements
This week, various analysts provided updated stock ratings and price targets for several companies. Notably, an increase in price target to $150 for Tesla (TSLA) indicates a bullish outlook. In addition, Apple (AAPL) saw a price target increase of 10% from $175 to $192 according to a recent report. These changes reflect analysts' confidence in the companies' performance, which could influence investor sentiment and market movements.
Read More: Street Calls of the Week Highlight Key Stock Movements
CrowdStrike (CRWD) Price Target Increased on Strong Guidance
Bernstein has raised its price target for CrowdStrike (CRWD) due to strong guidance provided by the company. This adjustment reflects the firm's confidence in CrowdStrike's projected growth and the overall performance in the cybersecurity market. A new price target, which indicates expected upside, could influence investor sentiment and trading volumes. As a result, this may lead to potential positive impacts on CRWD's stock price in upcoming trading sessions.
Read More: CrowdStrike (CRWD) Price Target Increased on Strong Guidance
Broadcom (AVGO) Price Target Raised Post Earnings Sell-off
Despite a sell-off following its recent earnings report, Broadcom (AVGO) has had its price target raised. Analysts believe that the long-term growth potential remains strong, supporting the updated price target. The company reported quarterly revenue growth, reflecting resilience in its demand. This adjustment may positively influence market perceptions and future trading strategies for investors in the semiconductor sector, particularly concerning AVGO's performance.
Read More: Broadcom (AVGO) Price Target Raised Post Earnings Sell-off
Figma Price Target Cut by Wall Street: Market Implications
Wall Street has recently adjusted Figma’s price target, impacting investor sentiment. Historical trends suggest that revisions like this could present a buying opportunity for investors. It is essential for market participants to note how such adjustments can indicate future performance and market movements. This could lead to increased trading volumes depending on investor reactions and changes in strategy surrounding Figma's operations in the tech sector.
Read More: Figma Price Target Cut by Wall Street: Market Implications
Voyager Technologies (VYGR) Price Target Raised Due to Backlog Strength
Wedbush increased the price target for Voyager Technologies (VYGR) owing to a robust backlog. This adjustment reflects confidence in the company's operational capacity and future revenue potential. The financial community often closely monitors such changes as they can influence investor sentiment and trading volumes. A higher price target may also attract new investors, impacting market dynamics surrounding VYGR.
Read More: Voyager Technologies (VYGR) Price Target Raised Due to Backlog Strength
Northern Trust (NTRS) stock outlook amid rising targets for 2023
Northern Trust (NTRS) has seen an increase in stock price targets by analysts amid a favorable economic outlook. Recent reports indicate an average target price of $95, reflecting a potential upside of 15% from current levels. The company's strong fundamentals, including a stable P/E ratio of 14.5, position it well within the financial sector. This rise in target prices is crucial as it may influence investor sentiment and drive trading volumes in the short term.
Read More: Northern Trust (NTRS) stock outlook amid rising targets for 2023
Lowe's (LOW) Earnings Beat Estimates with $23.08B Revenue Report
Lowe's Companies, Inc. (NYSE:LOW) reported first-quarter revenue of $23.08 billion, surpassing estimates of $22.97 billion, with earnings per share of $3.03, exceeding the forecast of $2.97. The company has seen a decline of 4.3% in shares over the past year and 11.9% year-to-date. Analysts have recently adjusted price targets, with Truist lowering its target from $293 to $280 while maintaining a Buy rating, and Citi upgrading its rating to Buy from Neutral with a target of $285. Despite overall market pressures, these results and adjustments may positively influence investor sentiment towards LOW.
Read More: Lowe's (LOW) Earnings Beat Estimates with $23.08B Revenue Report
PANW Price Target Raised to $253 on Firewall Demand Trends
Morgan Stanley raised its price target for Palo Alto Networks (PANW) to $253 from $223 on May 20, suggesting a 2% upside from the May 18 close of $247.55. This upgrade comes as PANW is expected to report fiscal third-quarter results on June 2, with analysts anticipating a significant performance, particularly in remaining performance obligations growing closer to 33% year over year. The motivations behind the price target increase include strong demand across firewall refreshes and AI security solutions. The upgrade reflects confidence in Palo Alto's growth relative to strong performances from competitors like Fortinet and Cisco.
Read More: PANW Price Target Raised to $253 on Firewall Demand Trends
Marvell (MRVL) Price Target Raised to $210 on Data Center Growth
Stifel has raised Marvell Technology's (MRVL) price target to $210, citing expected growth in the data center segment. This adjustment reflects analysts' optimism about Marvell's expanding portfolio and its impact on revenue. The increase in the price target could influence investor sentiment and stock performance. As data center demand rises, Marvell's position may strengthen within the semiconductor industry.
Read More: Marvell (MRVL) Price Target Raised to $210 on Data Center Growth
Nvidia (NVDA) Price Target Increased to $400 Due to TAM Growth
Melius has raised its price target for Nvidia (NVDA) to $400, citing growth in total addressable market (TAM) as the primary driver. This adjustment reflects expectations for increased demand in sectors where Nvidia operates. Analysts utilize price targets to influence investment decisions, and this increase might lead to positive sentiment among investors. As such, the updated target could have implications on trading volumes and investor interest in NVDA moving forward.
Read More: Nvidia (NVDA) Price Target Increased to $400 Due to TAM Growth
Celcuity (CELC) Stock Target Increased to $185 by H.C. Wainwright
H.C. Wainwright has raised the price target for Celcuity (CELC) to $185. This adjustment reflects analysts' positive outlook on the company's future performance. The raised target could impact investor sentiment and trading volumes in the stock. Changes in price targets are significant as they can influence market behavior and investor decisions.
Read More: Celcuity (CELC) Stock Target Increased to $185 by H.C. Wainwright
Plug Power (PLUG) Stock Rallies 21.1% Following Strong Q1 Results
Plug Power (PLUG) stock increased by 21.1% this week, outperforming the S&P 500, which rose 0.1%, and the Nasdaq, which fell 0.1%. The company's first-quarter results, released on May 11, showed sales of $163.5 million, exceeding analysts' expectations of $140 million. Plug Power reported a net loss of $109 million, slightly better than the predicted loss of $110 million. Following the earnings report, multiple investment firms upgraded their price targets, with B. Riley raising its target from $3 to $5, indicating a potential 32% upside.
Read More: Plug Power (PLUG) Stock Rallies 21.1% Following Strong Q1 Results
AppLovin (APP) Price Target Raised to $515 After Q1 Earnings Beat
AppLovin Corporation (APP) received a price target increase to $515 from $500 by JPMorgan following a first-quarter earnings report that exceeded expectations. In Q1, APP outperformed its earnings per share (EPS) by $0.12, and projected revenues are estimated between $1.915 billion and $1.945 billion for the upcoming period. Deutsche Bank and Piper Sandler also raised their price targets for APP to $660 and $665 respectively. CEO Adam Foroughi announced that starting June, advertisers can use the new Axon platform to launch campaigns, which is anticipated to significantly impact company growth.
Read More: AppLovin (APP) Price Target Raised to $515 After Q1 Earnings Beat
Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Eli Lilly and Company (LLY) received a price target increase to $1,400 from $1,350 by Barclays following strong first-quarter results. Goldman Sachs reiterated a Buy rating with a target of $1,283, stating that the stock's recent weakness seems overblown. The company revised its 2026 full-year revenue guidance to $82-85 billion, indicating a 28% growth from 2025. Additionally, LLY's non-GAAP EPS is estimated between $35.50 and $37, higher than previous estimates, reflecting robust performance across its therapeutic areas.
Read More: Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Mastercard (MA) Earns Outperform Rating with $580 Price Target
Mastercard Incorporated (MA) received an Outperform rating from BMO Capital on May 5, with a price target set at $580. The company reported strong Q1 results, surpassing both revenue and earnings expectations. Analysts have noted Mastercard's heightened exposure to Middle East travel, which may impact future performance. Other firms, like Macquarie and UBS, adjusted their price targets to $665 and $640 respectively while maintaining positive ratings, reflecting continued confidence in Mastercard's long-term potential.
Read More: Mastercard (MA) Earns Outperform Rating with $580 Price TargetFrequently asked questions
How accurate are price targets?
Not very. They are an analyst’s best guess, and stocks often miss them by a wide margin. They are most useful as a sign of which way opinion is moving.
Why does a stock move when a target is raised?
A higher target can bring in new buyers, especially from a well-known analyst. The move is often small and short, unless the note also changes the rating.